E6/E7 mRNA Performance to Detect HSIL and Cost-effectiveness Analysis of This Screening Strategy in HIV + MSM

Hiv Clinical Trial

— ELAVI-67  

Official title:

Performance of E6/E7 mRNA to Detect Anal High-Grade Intraepithelial Lesions and Cost-effectiveness Analysis of a New Screening Strategy for Anal Cancer in HIV Positive Men Who Have Sex With Men

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03357991
• Other study ID #: PR076/17
• Secondary ID: PI16/01056
• Status: Recruiting
• Phase: N/A
• First received: November 24, 2017
• Last updated: December 5, 2017
• Start date: January 11, 2015
• Est. completion date: June 2020

Study information

• Verified date: December 2017
• Source: Hospital Universitari de Bellvitge
• Contact: Ana C Silva Klug
• Phone: 0034932607667
• Email: ana.silva[@]bellvitgehospital.cat
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

This study evaluates the positive and negative predictive value of E6/E7 mRNA expression for anal HSIL and its capacity to predict incident HSIL in HIV + MSM. We also analyse the cost-effectiveness of this new screening strategy. It is an ambispective study with 355 participants and a follow-up period of 2 to 5 years.

Description:

Introduction: Anal cancer incidence is increasing in HIV-infected men who have sex with men (MSM). There are still no standardized criteria for anal cancer screening. Anal cytology has not shown enough sensitivity and specificity in the selection of patients who need more invasive procedures, as high resolution anoscopy (HRA). Human Papillomavirus (HPV) E6 and E7 oncogenes deregulation is a crucial factor in neoplasic lesions progression.

Objectives: 1)To assess the negative and positive predictive value of E6/E7 mRNA expression for high-grade squamous intraepithelial lesions (HSIL) and its capacity to predict the incidence of new HSIL during the follow-up 2)To analyze the cost-effectiveness of E6/E7 as a new screening strategy for anal cancer compared with usual strategies (cytology and DNA detection).

Methodology: Ambispective longitudinal study. Participants: HIV MSM from the outpatients HIV and STD Unit of Bellvitge Hospital. We include patients visited within the usual outpatient practice since January 2015 with a cytology stored following the Hospital protocol, as well as patients collected prospectively since January 2017. This methodological approach will let to reduce the time of inclusion and maximize follow-up time. Sample size calculated: 355 participants. Follow-up period: 2 to 5 years. At each visit an anal smear for cytology, HPV DNA detection (by Linear Array and Hybrid Capture) and E6/E7 mRNA expression and a HRA with biopsy of suspicious areas of dysplasia will be performed. The analysis of cost-effectiveness will be made with a Markov model that projects long-term cost and effectiveness for both strategies, the E6/E7 and conventional cytology plus detection of High Risk HPV.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 355
• Est. completion date: June 2020
• Est. primary completion date: June 2020
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Men who have sex with men >= 18 years

• HIV documented infection

• Signature of the informed consent

Exclusion Criteria:

• Previous diagnosis of anal cancer.

• Treatment of anal intraepithelial lesions the 5 years before study inclusion.

• Suspect infiltrating anal cancer, requiring exploration under anesthesia and surgical removal for histological confirmation.

• History of diffuse ano-genital condylomatous disease the 5 years before study inclusion or presence at first visit.

• Other factors that could prevent correct diagnosis and monitoring of the anal dysplastic lesions (test intolerance, proctological pathology that does not allow HRA, etc.).

Related Conditions & MeSH terms

• Anal Cancer
• Anus Neoplasms
• Hiv
• HPV - Anogenital Human Papilloma Virus Infection
• HSIL, High Grade Squamous Intraepithelial Lesions
• Papilloma
• Papillomavirus Infections
• Squamous Intraepithelial Lesions of the Cervix
• Virus Diseases

Locations

Country	Name	City	State
Spain	Hospital Universitary de bellvitge	L'Hospitalet de Llobregat	Barcelona

Sponsors (2)

Lead Sponsor	Collaborator
Hospital Universitari de Bellvitge	Institut d'Investigació Biomèdica de Bellvitge

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determine the predictive value of HPV E6/E7 mRNA for the detection of HSIL and its ability to predict incident cases.	Determination of HPV E6/E7 ARNm in anal samples of 355 HIV + MSM. Correlation of the detection of HPV E6/E7 ARNm with the diagnosis of HSIL in this patients performing anal cytology an HRA at the first visit and during the follow-up.	2-5 years
Secondary	Cost-effectiveness analysis of an anal cancer screening strategy based on HPV E6/E7 mRNA analysis.	Cost-effectiveness analysis of an anal cancer screening strategy based on the selection of candidates for HRA according to the expression of the E6 / E7 mRNA, compared to the usual strategy based on cytology and DNA HPV detection.	2-5 years